Imagion Biosystems has lodged Notice to Optionholders — Pro-Rata Non-Renounceable Rights Issue.
View the Notice to Optionholders.
Letter to Option Holders — Rights Issue
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.